<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292225</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-18</org_study_id>
    <nct_id>NCT02292225</nct_id>
  </id_info>
  <brief_title>Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)</brief_title>
  <official_title>A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in&#xD;
      combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic&#xD;
      Lymphoma previously treated with a BTKi.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b, open-label, dose escalation, safety and tolerability study of Duvelisib&#xD;
      (IPI-145) in combination with obinutuzumab in subjects with Chronic Lymphocytic&#xD;
      Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The scope of the program has been reduced to focus resources on studies which can potentially&#xD;
    enable the registration of duvelisib.&#xD;
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 30 days from last dose of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years from the first dose of study treatment or until study treatment is completed, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BTK mutation status</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of duvelisib and IPI-656 (major metabolite)</measure>
    <time_frame>Week 1, Week 2, Months 2, 4, 7, 11, 15, 19</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Lymphocytic Leukemia, Chronic</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <arm_group>
    <arm_group_label>IPI-145 in Combination with Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145 (duvelisib)</intervention_name>
    <description>25mg and/or 5mg oral capsule</description>
    <arm_group_label>IPI-145 in Combination with Obinutuzumab</arm_group_label>
    <other_name>Duvelisib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>1000mg/40mL single-use vials</description>
    <arm_group_label>IPI-145 in Combination with Obinutuzumab</arm_group_label>
    <other_name>GAZYVA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Diagnosis of Chronic lymphocytic leukemia or Small lymphocytic lymphoma that meets at&#xD;
             least one of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008&#xD;
             criteria for treatment (Binet Stage ≥ B and/or Rai Stage ≥ I with symptoms)&#xD;
&#xD;
          -  Measurable disease with a lymph node or tumor mass &gt;1.5 cm in at least one dimension&#xD;
             as assessed by computed tomography (CT)&#xD;
&#xD;
          -  Previous exposure to BTKi therapy and meets at least one of the below criteria:&#xD;
&#xD;
               -  Progressive disease while receiving a BTKi therapy, or stable disease as best&#xD;
                  response after 12 months of receiving a BTKi therapy&#xD;
&#xD;
               -  Discontinued a BTKi therapy due to BTKi treatment-related intolerance&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (corresponds to&#xD;
             Karnofsky Performance Status [KPS] ≥60%)&#xD;
&#xD;
          -  Subjects must be able to receive outpatient treatment and laboratory monitoring (where&#xD;
             specifically indicated) at the institution that administers study drug for the entire&#xD;
             treatment period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Richter's transformation or prolymphocytic leukemia&#xD;
&#xD;
          -  Refractory to obinutuzumab (defined as progression or relapse &lt;12 months of receiving&#xD;
             obinutuzumab monotherapy or &lt;24 months of receiving an obinutuzumab-containing&#xD;
             regimen)&#xD;
&#xD;
          -  Progressive disease while previously receiving a PI3K inhibitor (e.g. GS-1101&#xD;
             [idelalisib], duvelisib) or a serious/severe AE related to PI3K inhibitor treatment&#xD;
&#xD;
          -  History of severe reaction to prior monoclonal antibody therapy (defined as a Grade 4&#xD;
             event and/or requiring permanent discontinuation)&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) or Human T Cell Lymphotropic Virus 1 (HTLV-1)&#xD;
             infection&#xD;
&#xD;
          -  Prior, current, or chronic hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  History of tuberculosis treatment within the preceding 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cohan, MD</last_name>
    <role>Study Director</role>
    <affiliation>SecuraBio Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1b, CLL/SLL, PI3K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

